US2010008947A1PendingUtilityA1

Porcine adenovirus e1 and e4 regions

61
Individually held — no corporate assignee on recordPriority: Sep 24, 2001Filed: Jun 19, 2009Published: Jan 14, 2010
Est. expirySep 24, 2021(expired)· nominal 20-yr term from priority
Inventors:Suresh Tikoo
C12N 7/00A01K 2227/108C07K 14/005C12N 15/86C12N 2710/10322C12N 2710/10343C12N 2710/10361
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to the characterization of the porcine adenovirus E1 and E4 regions. The complete nucleotide sequence of the genome of porcine adenovirus type 3 (PAV-3), providing the characterization of the PAV3 E1 region, is described herein. Methods for construction of infectious PAV genomes by homologous recombination in procaryotic cells are provided. Recombinant PAV viruses are obtained by transfection of mammalian cells with recombinant PAV genomes. The PAV-3 genome can be used as a vector for the expression of heterologous nucleotide sequences, for example, for the preparation and administration of subunit vaccines to swine or other mammals.

Claims

exact text as granted — not AI-modified
1 . A composition capable of inducing an immune response in an animal subject, said composition comprising a replication-defective recombinant PAV vector, wherein the PAV vector lacks E1A function and retains E1B small  function and wherein the vector comprises a heterologous nucleotide sequence that encodes an immunogenic polypeptide; and a pharmaceutically acceptable vehicle. 
     
     
         2 . The composition of  claim 1 , wherein the animal subject is a mammalian subject. 
     
     
         3 . A composition capable of inducing an immune response in an animal subject, said composition comprising a replication-defective recombinant PAV vector, wherein the vector lacks E1B large  function and wherein the vector comprises a heterologous nucleotide sequence that encodes an immunogenic polypeptide; and a pharmaceutically acceptable vehicle. 
     
     
         4 . The composition of  claim 3 , wherein the animal subject is a mammalian subject. 
     
     
         5 . A composition capable of inducing an immune response in an animal subject, said composition comprising a replication-defective recombinant PAV vector, wherein the PAV vector lacks E4 ORF3 function and wherein the vector comprises a heterologous nucleotide sequence that encodes an immunogenic polypeptide; and a pharmaceutically acceptable vehicle. 
     
     
         6 . The composition of  claim 5 , wherein the animal subject is a mammalian subject. 
     
     
         7 . The composition of  claim 2 , wherein said immunogenic polypeptide is a pathogen antigen. 
     
     
         8 . The composition of  claim 4 , wherein said immunogenic polypeptide is a pathogen antigen. 
     
     
         9 . The composition of  claim 6 , wherein said immunogenic polypeptide is a pathogen antigen. 
     
     
         10 . A method for eliciting an immune response in a mammalian host comprising administering a composition according to  claim 2  to said host. 
     
     
         11 . A method for eliciting an immune response in a mammalian host comprising administering a composition according to  claim 4  to said host. 
     
     
         12 . A method for eliciting an immune response in a mammalian host comprising administering a composition according to  claim 6  to said host. 
     
     
         13 . A vaccine for protecting an animal host against infection comprising a replication-defective PAV, wherein the PAV vector lacks E1A function and retains E1B small  function and wherein said heterologous nucleotide sequence encodes an immunogenic polypeptide. 
     
     
         14 . The vaccine of  claim 13 , wherein the animal host is a mammalian host. 
     
     
         15 . A vaccine for protecting an animal host against infection comprising a replication-defective PAV, wherein the vector lacks E1B small  function and wherein said heterologous nucleotide sequence encodes an immunogenic polypeptide. 
     
     
         16 . The vaccine of  claim 15 , wherein the animal host is a mammalian host. 
     
     
         17 . A vaccine for protecting an animal host against infection comprising a replication-defective PAV, wherein the PAV vector lacks E4 ORF3 function and wherein said heterologous nucleotide sequence encodes an immunogenic polypeptide. 
     
     
         18 . The vaccine of  claim 17 , wherein the animal host is a mammalian host. 
     
     
         19 . A composition capable of inducing an immune response in an animal subject, said composition comprising a replication-defective recombinant PAV vector, wherein the PAV vector lacks E1A function and E1B large  function and wherein the vector comprises a heterologous nucleotide sequence that encodes an immunogenic polypeptide; and a pharmaceutically acceptable vehicle. 
     
     
         20 . The composition of  claim 19 , wherein the animal subject is a mammalian subject. 
     
     
         21 . The composition of  claim 20 , wherein said immunogenic polypeptide is a pathogen antigen. 
     
     
         22 . A method for eliciting an immune response in a mammalian host comprising administering a composition according to  claim 20  to said host. 
     
     
         23 . The composition of  claim 19 , wherein the PAV vector further lacks E1B small  function. 
     
     
         24 . The composition of  claim 20 , wherein the PAV vector further lacks E1B small  function. 
     
     
         25 . The composition of  claim 24 , wherein said immunogenic polypeptide is a pathogen antigen. 
     
     
         26 . A method for eliciting an immune response in a mammalian host comprising administering a composition according to  claim 24  to said host. 
     
     
         27 . A vaccine for protecting an animal host against infection comprising a replication-defective PAV, wherein the PAV vector lacks E1A function and E1B large  function and wherein said heterologous nucleotide sequence encodes an immunogenic polypeptide. 
     
     
         28 . The vaccine of  claim 27 , wherein the animal host is a mammalian host. 
     
     
         29 . The vaccine of  claim 27 , wherein the PAV vector further lacks E1B small  function. 
     
     
         30 . The vaccine of  claim 28 , wherein the PAV vector further lacks E1B small  function.

Join the waitlist — get patent alerts

Track US2010008947A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.